Supertramp thanks for quoting me but you are not complete right IMO. The ASX does value certain biotech’s highly.
Take for example CSL. Current price $155. Market cap circa $50 billion. For people lucky to have got this stock at the float price in the early 90’s circa $2. Taking into account the 3 way split the stock price is actually over $450. Not bad from $2 float!!!
The difference is CSL is a bemoath with huge free cash flows, profits and global repute. The Aussie market values profit and cash flow in biotech’s.
The US market is larger and more willing to put a higher value on specs. So, yes Imugene would have probably been valued higher in a US listed market.
Told you so!! IMU heading to $200m Mkt Cap, page-43
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
-0.001(0.93%) |
Mkt cap ! $404.2M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.6¢ | 5.4¢ | $322.4K | 5.911M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 3689604 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 1067155 | 22 |
View Market Depth
| Last trade - 11.38am 30/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |